Relmada Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

19.03.24	Recap: Relmada Therapeutics Q4 Earnings (Benzinga)
18.03.24	Earnings Outlook For Relmada Therapeutics (Benzinga)
01.02.24	Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying (Benzinga)
31.05.18	Aqua-YIeld® and Tropical Star: A Lesson in Transplanting Success (PR Newswire)
03.04.18	Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer (PR Newswire)
17.01.18	Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System (PR Newswire)
09.01.18	Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms (PR Newswire)
27.10.17	Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms (PR Newswire)
05.10.17	Relmada Therapeutics Announces $6.9 Million Private Placement (PR Newswire)
28.06.17	Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program (PR Newswire)
21.06.17	Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics (PR Newswire)
15.06.17	Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors (PR Newswire)
18.05.17	Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company (PR Newswire)
13.04.17	Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
15.02.17	Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference (PR Newswire)
25.01.17	Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone (PR Newswire)
24.01.17	Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER (PR Newswire)
05.01.17	Relmada Therapeutics to Present at Biotech Showcase 2017 (PR Newswire)
29.11.16	Relmada Therapeutics to Present at LD Micro "Main Event" Investor Conference (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V